Turn this role into an interview — a resume and cover letter built around what this employer wants.
Chugai Pharmabody Research Pte. Ltd. (CPR) invites an IP Leader to join our in-house IP team in Singapore. You will support R&D through patenting strategy, filings, and global prosecution, working closely with Japan and Singapore offices to protect novel antibody technologies.
We seek a candidate with 6–8 years of patenting experience in biotechnology or pharmaceutical patents, strong drafting, and cross-border collaboration abilities. English and Japanese proficiency is essential for this role.
Chugai Pharmabody Research Pte. Ltd. (“CPR”) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai), a member of Roche group, in January 2012 and started operations on July 2, 2012. Located at Geneo in Singapore, it aims to generate new antibody drugs based on Chugai’s proprietary antibody engineering technologies, such as recycling antibody®, sweeping antibody®, bispecific antibody, various Fc engineered antibodies, and other new antibody engineering technologies that are under development.
CPR is seeking an IP Leader with strong expertise and experience in biotech/pharma patenting work to join our in-house IP team to support our growing R&D and IP activities as we further our vision to create innovative drugs that improve patients’ lives.
Possess either 2 of the following skills:
IP professional with strong passion in IP protection and medical science for creating and delivering innovative drugs to society which leads to saving patients suffering from unmet medical needs are highly desired. As frequent communication and liaison is expected between both the Singapore and Japan office, you should possess good command of both spoken and written English and Japanese, excellent organizational and communication skills, team player mindset, as well as the ability to multi-task.
For more information regarding our Company, you may refer to our website at:
http://chugai-pharmabody.com/
We regret that only short-listed candidates will be notified